NEOLEUKIN THERAPEUTICS INC (NLTX) Stock Analyst Ratings
USA - NASDAQ:NLTX - US64049K2033 - Common Stock
3.49 USD
+0.05 (+1.45%)
3.42 USD
-0.07 (-2.01%)
ChartMill assigns a Buy % Consensus number of 43% to NLTX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 1.53. This target is -56.16% below the current price.
NLTX was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about NLTX.
In the previous month the buy percentage consensus was at a similar level.
NLTX was analyzed by 6 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-05-09 | Mizuho | Maintains | Neutral |
| 2023-01-03 | Guggenheim | Downgrade | Buy -> Neutral |
| 2022-11-16 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2022-11-15 | Mizuho | Downgrade | Buy -> Neutral |
| 2022-11-15 | Guggenheim | Downgrade | Buy -> Neutral |
| 2022-11-15 | Stifel | Downgrade | Buy -> Hold |
| 2022-11-15 | Canaccord Genuity | Downgrade | Buy -> Hold |
| 2022-09-12 | B of A Securities | Downgrade | Buy -> Underperform |
| 2022-09-12 | HC Wainwright & Co. | Maintains | Buy |
| 2022-03-02 | Piper Sandler | Maintains | Overweight |
NEOLEUKIN THERAPEUTICS INC / NLTX FAQ
What is the average price target for NEOLEUKIN THERAPEUTICS INC (NLTX) stock?
6 analysts have analysed NLTX and the average price target is 1.53 USD. This implies a price decrease of -56.16% is expected in the next year compared to the current price of 3.49.
What is the consensus rating for NEOLEUKIN THERAPEUTICS INC (NLTX) stock?
The consensus rating for NEOLEUKIN THERAPEUTICS INC (NLTX) is 43.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.
How many analysts have analysed NEOLEUKIN THERAPEUTICS INC (NLTX)?
The number of analysts covering NEOLEUKIN THERAPEUTICS INC (NLTX) is 6.